对 M.S. Elnaggar 等人撰写的 "吉西他滨、PI3 激酶-Akt 通路抑制和人类胶质瘤细胞系中的辐射 "发表评论1。

IF 2.8 4区医学 Q2 ONCOLOGY

Medical Oncology Pub Date : 2024-09-23 DOI:10.1007/s12032-024-02503-5

M B Balaji, Neha Brahma, S Vimal

{"title":"对 M.S. Elnaggar 等人撰写的 \"吉西他滨、PI3 激酶-Akt 通路抑制和人类胶质瘤细胞系中的辐射 \"发表评论1。","authors":"M B Balaji, Neha Brahma, S Vimal","doi":"10.1007/s12032-024-02503-5","DOIUrl":null,"url":null,"abstract":"The combination of gemcitabine, PI3K-Akt pathway inhibitors, and radiation in human glioma cell lines shows potential to enhance radiation sensitivity in aggressive brain tumors. Inhibiting the overactive PI3K-Akt pathway may increase tumor vulnerability to treatment. However, variability in responses among different glioma cell lines highlights the need for personalized approaches. Future research should focus on identifying biomarkers to tailor treatment for individual patients. Additionally, addressing safety concerns and the challenges of translating preclinical findings into clinical practice is crucial. Further studies should explore the therapy's molecular mechanisms and evaluate its clinical potential.","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Comment on \\\"gemcitabine, PI3kinase-Akt pathway inhibition and radiation in human glioma cell lines\\\" by M.S. Elnaggar et al.1.\",\"authors\":\"M B Balaji, Neha Brahma, S Vimal\",\"doi\":\"10.1007/s12032-024-02503-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The combination of gemcitabine, PI3K-Akt pathway inhibitors, and radiation in human glioma cell lines shows potential to enhance radiation sensitivity in aggressive brain tumors. Inhibiting the overactive PI3K-Akt pathway may increase tumor vulnerability to treatment. However, variability in responses among different glioma cell lines highlights the need for personalized approaches. Future research should focus on identifying biomarkers to tailor treatment for individual patients. Additionally, addressing safety concerns and the challenges of translating preclinical findings into clinical practice is crucial. Further studies should explore the therapy's molecular mechanisms and evaluate its clinical potential.\",\"PeriodicalId\":18433,\"journal\":{\"name\":\"Medical Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12032-024-02503-5\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12032-024-02503-5","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在人类胶质瘤细胞系中联合使用吉西他滨、PI3K-Akt通路抑制剂和放射线，有可能提高侵袭性脑瘤对放射线的敏感性。抑制过度活跃的 PI3K-Akt 通路可能会增加肿瘤对治疗的脆弱性。然而，不同胶质瘤细胞系的反应存在差异，这凸显了个性化方法的必要性。未来的研究应侧重于确定生物标志物，以便为患者量身定制治疗方案。此外，解决安全性问题以及将临床前研究结果转化为临床实践所面临的挑战也至关重要。进一步的研究应探索该疗法的分子机制并评估其临床潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Comment on "gemcitabine, PI3kinase-Akt pathway inhibition and radiation in human glioma cell lines" by M.S. Elnaggar et al.¹.

The combination of gemcitabine, PI3K-Akt pathway inhibitors, and radiation in human glioma cell lines shows potential to enhance radiation sensitivity in aggressive brain tumors. Inhibiting the overactive PI3K-Akt pathway may increase tumor vulnerability to treatment. However, variability in responses among different glioma cell lines highlights the need for personalized approaches. Future research should focus on identifying biomarkers to tailor treatment for individual patients. Additionally, addressing safety concerns and the challenges of translating preclinical findings into clinical practice is crucial. Further studies should explore the therapy's molecular mechanisms and evaluate its clinical potential.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Medical Oncology 医学-肿瘤学

CiteScore

4.20

自引率

2.90%

发文量

259

审稿时长

1.4 months

期刊介绍： Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.